{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:24:47Z","timestamp":1789043087277,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>The best strategy for nonfunctioning, sporadic, G1-G2 pancreatic neuroendocrine tumors \u22642\u2009cm is unknown. An active surveillance is usually recommended. The PROMID and the CLARINET studies proved the value of somatostatin analog (SSA) treatment in advanced gastro-entero-pancreatic neuroendocrine tumors. The aim of this study is to assess the value of SSA in pancreatic NET (PanNET) \u2264 2\u2009cm.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We retrospectively collected data from 72 patients with sporadic nonfunctioning G1-G2 PanNETs \u2264 2\u2009cm, which were either treated with somatostatin analogs (n\u2009=\u200931) or underwent active surveillance (n\u2009=\u200941) at our institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At a median follow-up of 53.7\u2009months, the median progression-free survival was not reached in the treatment group versus an estimated progression-free survival of 85\u2009months in the control group (hazard ratio, 0.11; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.01), with a rate of progression or death up to 21.9% in the active surveillance group. Additionally, in the group of patients treated with somatostatin analogs, the response rate was 16.1% with 1 complete response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogs in patients with sporadic, nonfunctionating G1-G2 PanNETs \u2264 2-cm delaying tumor progression and distant spread in small lesions that sometimes may reveal unpredictable aggressiveness.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000002425","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T16:00:31Z","timestamp":1733241631000},"page":"e524-e529","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Somatostatin Analogs Versus Active Surveillance in Small Pancreatic Neuroendocrine Tumors"],"prefix":"10.1097","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-6629","authenticated-orcid":false,"given":"Maria Grazia","family":"Maratta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Raia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida A.","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli - IRCCS - Universit\u00e0 Cattolica del Sacro Cuore European NeuroEndocrine Tumor Society (ENETS) Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Brizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Rufini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina Grazia","family":"Giancipoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schinzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frediano","family":"Inzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Rindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7]]},"reference":[{"key":"bib1-20250625","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2010.166","article-title":"The origin of neuroendocrine tumors and the neural crest saga","volume":"24","author":"Rosai","year":"2011","journal-title":"Mod Pathol"},{"key":"bib2-20250625","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"bib3-20250625","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"bib4-20250625","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4251\/wjgo.v12.i8.791","article-title":"Gastrointestinal neuroendocrine tumors in 2020","volume":"12","author":"Ahmed","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"bib5-20250625","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"bib6-20250625","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1196\/annals.1294.025","article-title":"Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center","volume":"1014","author":"Pape","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"bib7-20250625","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1677\/ERC-07-0221","article-title":"Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors","volume":"15","author":"Halfdanarson","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"bib8-20250625","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bib9-20250625","doi-asserted-by":"crossref","first-page":"e13343","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"bib10-20250625","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib11-20250625","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"E-mail placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival long-term survival in the PROMID cohort","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"bib12-20250625","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","article-title":"Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study on behalf of the CLARINET investigators","volume":"71","author":"Caplin","year":"2020","journal-title":"Endocrine"},{"key":"bib13-20250625","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"bib14-20250625","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/diagnostics11020316","article-title":"Role of endoscopic ultrasound in the diagnosis of pancreatic neuroendocrine neoplasms","volume":"11","author":"Ishii","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"bib15-20250625","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"bib16-20250625","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"bib17-20250625","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","author":"Hofman","year":"2015","journal-title":"Radiographics"},{"key":"bib18-20250625","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib20-20250625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"bib21-20250625","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1245\/s10434-013-3005-7","article-title":"Population-level analysis of pancreatic neuroendocrine tumors 2\u2009cm or less in size","volume":"20","author":"Kuo","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"bib22-20250625","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"key":"bib23-20250625","first-page":"1009","article-title":"Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms (ASPEN) \u22642\u2009cm: study protocol for a prospective observational study","volume":"7","author":"Partelli","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"bib24-20250625","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.surg.2012.08.038","article-title":"Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management","volume":"152","author":"Lee","year":"2012","journal-title":"Surgery"},{"key":"bib25-20250625","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1634\/theoncologist.2019-0466","article-title":"Surgery versus surveillance for well-differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11-year analysis of the national cancer database","volume":"25","author":"Assi","year":"2020","journal-title":"Oncologist"},{"key":"bib26-20250625","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/archsurg.2011.102","article-title":"Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes","volume":"146","author":"Haynes","year":"2011","journal-title":"Arch Surg"},{"key":"bib27-20250625","doi-asserted-by":"crossref","first-page":"21932","DOI":"10.21037\/gs-20-582","article-title":"Risk of malignancy and prognosis of sporadic resected small (\u22642\u2009cm) nonfunctional pancreatic neuroendocrine tumors","volume":"10","author":"Liu","year":"2021","journal-title":"Gland Surg"},{"key":"bib28-20250625","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"bib29-20250625","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"bib30-20250625","doi-asserted-by":"crossref","first-page":"578","DOI":"10.21037\/jgo.2019.12.09","article-title":"Surgical management of primary pancreatic neuroendocrine tumors","volume":"11","author":"Johnston","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"bib31-20250625","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/SLA.0000000000000348","article-title":"Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs)","volume":"259","author":"Hashim","year":"2014","journal-title":"Ann Surg"},{"key":"bib32-20250625","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/bjs\/znac267","article-title":"Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2\u2009cm: interim analysis of prospective ASPEN trial","volume":"109","author":"Partelli","year":"2022","journal-title":"Br J Surg"},{"key":"bib33-20250625","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archsurg.141.8.765","article-title":"Resection of pancreatic neuroendocrine tumors: results of 70 cases","volume":"141","author":"Kazanjian","year":"2006","journal-title":"Arch Surg"},{"key":"bib34-20250625","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00268-012-1598-9","article-title":"Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors","volume":"36","author":"Inchauste","year":"2012","journal-title":"World J Surg"},{"key":"bib35-20250625","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/bjs\/znab088","article-title":"Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA)","volume":"108","author":"Heidsma","year":"2021","journal-title":"Br J Surg"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000002425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:00:28Z","timestamp":1750831228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000002425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000002425","relation":{},"ISSN":["1536-4828"],"issn-type":[{"value":"1536-4828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"2024-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}